Loading…
Loading…
SGMT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SGMT and 80,000+ other tickers.
See exactly how SGMT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SGMT and 80,000+ other tickers.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor…
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet's Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company's Series A common stock be granted on August 17, 2026 to the newly hired employees.
Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).